Metavention provides a minimally invasive renal (and hepatic) denervation procedure using its proprietary iRF Denervation System, which delivers radio‑frequency energy with integrated cooling to permanently disrupt overactive sympathetic nerves. The one‑time outpatient treatment aims to lower blood pressure and improve metabolic parameters in patients with resistant hypertension or uncontrolled type 2 diabetes, offering an alternative to additional medication.
Funding
$65M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
3OFounders
Product
Problem
Hypertension and type 2 diabetes affect millions worldwide, and a significant subset of patients do not achieve adequate control with lifestyle changes and medication, leading to high rates of cardiovascular complications and premature death.
Solution
Metavention offers a minimally invasive renal (and hepatic) denervation procedure that uses its proprietary iRF Denervation System to deliver radio‑frequency energy and simultaneous cooling to targeted overactive sympathetic nerves around the renal artery. By permanently disrupting these nerves, the treatment aims to lower blood pressure and improve metabolic parameters associated with type 2 diabetes. The system’s multi‑electrode catheter provides circumferential energy delivery for uniform nerve ablation while protecting the arterial wall. Clinical studies in the United States, New Zealand, and Australia evaluate safety and efficacy, offering patients an alternative to additional medication. The procedure is performed as a single outpatient session, reducing the need for ongoing drug therapy and associated side effects.
Target Audience
Primary customers are interventional cardiologists, electrophysiologists, and vascular surgeons treating patients with resistant hypertension or uncontrolled type 2 diabetes, as well as hospitals and specialty clinics seeking non‑pharmacologic therapeutic options.
Features
- Multi‑electrode iRF catheter that delivers controlled radio‑frequency energy to renal (and hepatic) sympathetic nerves
- Integrated cooling circuit that removes heat to safeguard the arterial wall during ablation
- Uniform circumferential energy distribution for consistent nerve disruption
- One‑time, minimally invasive outpatient procedure with no permanent implants
- Ongoing FDA‑cleared clinical trials assessing safety and performance for hypertension and type 2 diabetes
- Compatibility with standard catheterization lab equipment and imaging guidance